Downstream of Bid (DOBI) known as
INTRODUCTION
TRAIL, which belongs to the tumor necrosis factor (TNF) superfamily, can induce apoptotic cell death in a variety of tumor cells; however, it exerts limited toxicity against normal cells. The engagement of TRAIL with death receptors DR4 and DR5 recruits the adaptor protein FADD and procaspase-8 to form the death-inducing signaling complex (DISC), in which procaspase-8 activation takes place. Activated caspase-8 then cleaves fulllength Bid to generate the truncated form of Bid (tBid), which causes mitochondrial dysfunction by enhancing the permeability of the mitochondrial outer membrane (1) . Permeabilization of the mitochondrial outer membrane results in the release of mitochondrial pro-death molecules, such as cytochrome c and Smac from the mitochondria into the cytosol. The released mitochondrial pro-death molecules lead to the activation of downstream caspases, such as caspases-9 and -3. For example, cytochrome c that has been released from the mitochondria binds to Apaf-1 with procaspase-9 and ATP. This results in the formation of a large complex, an apoptosome, which causes the activation of procaspase-9 and subsequently procaspase-3 (2, 3) .
During the search for modulators of TRAIL death signaling using synthetic small interference RNA (siRNA), DOBI was identified as a protein that was necessary for the release of cytochrome c to occur downstream of tBid. Specifically, introduction of DOBI siRNA into HeLa cells allowed the activation of procaspase-8 and Bid cleavage, but blocked the release of cytochrome c from the mitochondria in response to TRAIL (4) . DOBI is also known as pseudouridine synthase 10 (Pus10), because it contains a conserved region that is found in pseudouridine synthases (5) . Analysis of the crystal 3D structure of DOBI revealed that it has a crescent shape with two functional domains, a pseudouridine synthase catalytic domain and a THUMP-containing domain, which suggests that DOBI catalyzes the pseudouridination of tRNA or other RNA molecules. Indeed, a recent study showed that archaeal Pus10 has the tRNA pseudouridine 54 synthase activity in vitro (6) .
In this study, we investigated the changes in DOBI that occur during TRAIL-induced cell death in HeLa cells and found that DOBI is cleaved by caspases-3 and -8. These results may provide an insight into the role that DOBI plays in TRAIL-induced cell death.
RESULTS AND DISCUSSION
To evaluate the functional role that DOBI plays in TRAIL death signaling, we purchased the AK056874/FLJ32312 clone from the National Institute of Technology and Evaluation, Chiba, Japan, and then constructed the bacterial expression vector pET30(a)+ : DOBI to purify the recombinant DOBI protein (an approximate molecular weight of 60.2 kD). The denatured and native forms of the recombinant DOBI protein expressed in E. coli were purified (Fig. 1A ) and used to generate polyclonal antibody against DOBI in rabbits. The polyclonal DOBI anti-http://bmbreports.org , after which Western blot analysis was performed using anti-HA antibody or anti-DOBI antibody. * and ** indicate HA tagged DOBI and endogenous DOBI, respectively. (C) Human tissue samples (50 μg) were purchased from Clontech (Mountain View, CA, USA), and Western blot analysis was performed using anti-DOBI antibody. B; brain, H; heart, Lu; lung, Li; liver, K; kidney, Sp; spleen, O; ovary, Te; testis, Sm; skeletal muscle (D) Lysates (100 μg) prepared from the indicated cell lines were used for Western blot analysis with anti-DOBI antibody.
body was then further purified by use of an activated-CH-sepharose 4B column conjugated with the purified DOBI protein.
Polyclonal DOBI antibody was then confirmed to recognize the endogenous DOBI and exogenous HA-tagged DOBI that was ectopically expressed in HCT116, whereas the HA antibody recognized only exogenous HA-tagged DOBI (Fig. 1B) . Western blot analysis revealed that DOBI is expressed in various tissues, including heart, lung, kidney, spleen, ovary and testis, as well as in skeletal muscles (Fig. 1C ) and in various tumor cell lines including HeLa, HCT116, A549, PC-3, and MCF-7 (Fig. 1D) .
Aza-Blanc et al. demonstrated that synthetic DOBI siRNA prevents the release of cytochrome c from the mitochondria in response to TRAIL, even in the presence of tBid activated by caspase-8. This suggests that DOBI is required for the tBid-mediated release of cytochrome c that occurs during TRAIL-induced cell death (4). To confirm whether DOBI is necessary for TRAIL-induced cell death, we constructed the plasmid vector, pc6 : EGFP-DOBI : shRNA, which expresses the DOBI : shRNA under the H1 promoter from pSUPER vector (7) and EGFP under the CMV promoter derived from pcDNA6 His-Myc.A (Invitrogen, Carlsbad, CA, USA). To generate stable cell lines that exhibit the reduced expression of DOBI by DOBI : shRNA in HeLa cells, HeLa cells transfected with either the control vector or pc6 : EGFP-H1 : DOBI : shRNA vector were selected for blastacidin and EGFP expression. Next, the reduced DOBI expression was confirmed by Western blot analysis ( Fig. 2A, 
right panel). Parental HeLa cells or HeLa cells transfected with pc6 : EGFP-H1
showed a significant amount of TRAIL-induced cell death; however, clones (# 51, # 59, # 60) that exhibited the reduced expression of DOBI with DOBI : shRNA showed a reduction of TRAIL-induced cell death ( Fig. 2A) . This result is consistent with the results of previous studies, which demonstrated that DOBI is a necessary protein in TRAIL-induced cell death (4). Next, we investigated the effects of ectopic overexpression of DOBI on cell death triggered by various death ligands. As shown in Fig. 2B , ectopic expression of DOBI in HeLa cells exhibited little or no effects on cell death triggered by TRAIL, α-Fas (CH11), or TNF-α/CHX. Aza-Blanc et al. suggested that DOBI is required for the release of cytochrome c during TRAIL-induced cell death (4); therefore, we evaluated DOBI to determine if it directly caused the release of cytochrome c from the mitochondria. To accomplish this, an in vitro cytochrome c release assay was adapted using the recombinant DOBI and isolated mitochondria. Under conditions in which the full-length Bid could release cytochrome c from the mitochondria, DOBI was not able to release cytochrome c (Fig. 3) , which suggests that DOBI cannot directly cause the release of cytochrome c by itself.
There are many proteins that are cleaved during cell death, and the cleaved proteins acquire the novel cell death-promoting or -inhibiting activities. The best example is the cleavage of Bid by caspase-8 to generate tBid, which is the most potent protein for permeabilization of the mitochondrial outer membrane (8) (9) (10) . To investigate the changes in DOBI that occur during cell death, HeLa cells were treated with TRAIL or etoposide. Approximately 6 hours after treatment with TRAIL, the full-length DOBI was obviously decreased, and after ap-http://bmbreports.org BMB reports After centrifugation at 10,000 × g for 10 minutes, the supernatants (sup) were separated from mitochondrial pellets, and the amounts of cytochrome c in both the supernatants and pellets were then analyzed by Western blot using anti-cytochrome c antibody.
proximately 24 hours the cleaved DOBI band (about 54 kD) was clearly observed (Fig. 4A) . Moreover, approximately 48 hours after treatment with etoposide, the full-length DOBI was completely cleaved into the 54 kD cleaved DOBI (Fig. 4B) . When TRAIL-induced cell death was inhibited by zVAD-fmk, a pan-caspase inhibitor, the cleavage of DOBI was completely blocked; this suggests that caspases may directly or indirectly participate in DOBI cleavage (Fig. 4C) . To determine if caspases can directly cleave the full-length DOBI, recombinant DOBI was subjected to recombinant active caspase-3 or -8 in vitro. Interestingly, caspases-3 and -8 were able to directly cleave the DOBI into the 54 kD cleaved DOBI, similar to the cleavage of the full-length Bid protein to tBid that occurs in response to treatment with caspases-3 and -8 (Fig. 4D) .
Although DOBI appears to have an enzymatic activity that induces the conversion of uridine in tRNA to pseudouridine, our results provide evidence that DOBI is a modulator of TRAIL death signaling. However, it is unclear whether this enzymatic activity of DOBI is directly involved in the modulation of TRAIL death signaling or not. Our results revealed that the recombinant DOBI is not able to cause the release of cytochrome c from isolated mitochondria (Fig. 3) , and ectopic expression of DOBI does not promote the induction of TRAIL-induced cell death in HeLa cells (Fig. 2B) . These findings suggest that enzymatic activity of DOBI is not directly associated with TRAIL death signaling. However, the fact that the reduced expression of DOBI using synthetic siRNA (4) or shRNA ( Fig. 2A) inhibits TRAIL-induced cell death indicates that DOBI may be converted into a modified DOBI that exerts an effect on mitochondrial events via tBid during cell death. This modification may provide a novel death-promoting activity to DOBI. One plausible modification of DOBI that may lead to its activation is its cleavage, since TRAIL activates several caspases that cleave target proteins during apoptotic cell death. Indeed, cleaved DOBI (54 kD) was found in HeLa cells that had been treated with TRAIL or etoposide ( Fig. 4A and 4B) . Moreover, the observed cleavage was mediated directly by caspases-3 or -8 ( Fig. 4C and 4D ). Because DOBI siRNA blocks the release of cytochrome c, even in the presence of tBid cleaved by caspase-8 (4), the cleaved DOBI may cooperate with tBid to maximize the mitochondrial dysfunction dur-http://bmbreports.org Fig. 4. (A, B) HeLa cells were treated with TRAIL (100 ng/ml) (A) or etoposide (30 μg/ml) (B), and Western blot analysis was then performed using anti-DOBI antibody. (C) HeLa cells were treated with TRAIL (100 ng/ml) in the presence or absence of zVAD-fmk (25 μM), after which Western blot analysis was performed using anti-DOBI antibody and anti-caspase-3 antibody. (D) The recombinant DOBI (7 μg) or Bid (7 μg) were treated with active recombinant caspases-3 (3.5 μg) or -8 (2.2 μg) in the presence or absence of zVAD-fmk (7.5 μM), and then incubated at 37 o C for 2 hours. Western blot analysis was performed using anti-DOBI antibody and anti-Bid antibody.
ing cell death. Based on these findings, it would be interesting to identify the sites at which DOBI is cleaved by caspases-3 and -8 and to determine whether the cleaved DOBI (either the N-terminal or C-terminal portion) can directly release cytochrome c from the mitochondria, or enhance the ability of tBID to release cytochrome c; this could be the focus of a future study, as shown in a proposed model (Fig. 5) . Taken together, our findings suggest that a pre-modified form of DOBI in healthy cells maintains the enzymatic activity of converting uridine found in tRNA to pseudouridine; but, DOBI is modified into a new form of DOBI that may cooperate with tBid during TRAIL-induced cell death.
MATERIALS AND METHODS

Cell culture and transfection
HeLa cells or indicated cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 100 units/ml of penicillin, and 100 μg/ml of streptomycin at 37 o C under 5% CO2 in a humidified incubator. HeLa cells were then transfected with the indicated vectors (pc6 : EGFP-H1-DOBI : shRNA, pcDNA6-HA-DOBI) using Effectene (Qiagen, Chatsorth, CA, USA) according to the manufacturer's instructions.
Purification of recombinant DOBI protein and generation of polyclonal antibody against DOBI
The open reading frame of DOBI was amplified using the template AK056874/FLJ32312 clone, which was purchased from the National Institute of Technology and Evaluation, Chiba, Japan. Following amplification, the ORF was cloned into pET30a(+) (Novagen, EMD chemicals, San Diego, USA) at the BamH1 and Xho1 sites. The DOBI protein was then expressed in E. coli BL21 (DE3), with protein induction being initiated by the addition of 0.8 mM IPTG for three hours. A His-Bind resin affinity column was then used to purify the expressed proteins (Novagen, EMD Chemicals, San Diego, USA). The purified recombinant protein (300 μg) was used to immunize the rabbits with complete Freund's adjuvant for priming immunization and incomplete Freund's adjuvant for the next boosting immunizations. The rabbits were subsequently sacrificed to obtain the blood serum. Anti-DOBI serum (10 ml) was further purified using an activated-CH-sepharose 4B column conjugated with the recombinant DOBI protein (1 mg).
Construction of pc6 : EGFP-H1 : DOBI : shRNA
Vector pc6 : EGFP-H1 was designed to express the enhanced green fluorescent protein (EGFP) under the CMV promoter and short hairpin interference RNA (shRNA) under the H1 promoter. A DOBI shRNA cassette was then generated by annealing the following two oligonucleotides containing DOBI target sites (19 bp indicated as bold line): 5'-GATCCCCAGACCTACAGT GCCTTAATTTCAAGAGAATTAAGGCACTGTAGGTCTTTTTT GGAAAT-3' 5'-ATTTCCAAAAAAGACCTACAGTGCCTTAATT CTCTTGAAATTAAGGCACTGTAGGTCTGGGGATC-3'. http://bmbreports.org BMB reports 
Cell death assay
The percentage of cell death was determined by counting EGFP-positive dead cells with apoptotic morphology using fluorescent microscopy. At least 300 cells in three separate fields were counted for each measurement.
Cytochrome c release assay
Cytochrome c release assay was performed as described previously (5). Briefly, isolated mitochondria, which had been treated with recombinant DOBI or Bid protein, were incubated at 30 o C for 1 hour in mitochondria regeneration buffer (250 mM sucrose, 10 mM HEPES-NaOH, pH 7.5, 2 mM KH2PO4, 5 mM sodium succinate, and 25 μM EGTA). After centrifugation at 10,000 × g for 10 minutes, the supernatants and pellets were subjected to SDS-PAGE, after which the released cytochrome c was visualized by Western blot analysis.
Reagents
The caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl (β-methyl ester)-fluoromethyl ketone (zVAD-fmk) was purchased from Calbiochem (San Diego, CA, USA). Anti-cytochrome c antibody and anti-Fas antibody (CH11) were purchased from BD Biosciences (Franklin Lakes, NJ, USA). TNF-α was purchased from R&D Systems (Minneapolis, MN, USA) . Except where noted, all other reagents were obtained from Sigma Chemical (St. Louis, MO, USA).
